SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Divi's Laboratories inks pact with global pharma company

26 May 2025 Evaluate

Divi's Laboratories has signed long term manufacturing and supply agreement with a global pharma company. Under this agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. The cost of capacity addition for manufacturing under this agreement is estimated to be Rs 650 to Rs 750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement.

Divi's Laboratories is one of the leading pharmaceutical companies in the world.

Divis Lab Share Price

6281.35 52.40 (0.84%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×